Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto legal cases where a farmer was found to be willfully infringing Monsanto's patent, the damages awarded to Monsanto were found to be non-dischargeable in the farmer’s Chapter 7 bankruptcy, as they "fell within the Bankruptcy Act’s exception for willful and malicious injuries." Monsanto has been criticized for a mistaken lawsuit. In 2002, Monsanto mistakenly sued Gary Rinehart of Eagleville, Missouri for patent violation. Rinehart was not a farmer or seed dealer, but sharecropped land with his brother and nephew, who were violating the patent. Monsanto dropped the lawsuit against him when it discovered the mistake. It did not apologize for the mistake